Pharmafile Logo

Combination therapies in oncology: The benefits of integrated insights

14 June 2018
11am EDT | 8am PDT | 4pm BST | 5pm CE


In association with Pharmaceutical Executive

Register now: https://bit.ly/2L80Tme

Most experts believe combination therapies to be the future of oncology treatment. But with a number of new compounds approved and hundreds more in development, it’s difficult for many to identify which combinations and in what sequence, will form future treatment paradigms. In addition, the rising costs of newer agents and increased cost pressure creates an environment ripe for payer management.

In this webinar, pharma market research experts Anthony Greenwood, Dr Chris Gaj and  Brett Gardiner will look at the challenges and opportunities for effectively launching combination therapies across tumor types and, referencing their experience in oncology, demonstrate how integrated insights from payers, KOLs, community oncologists and patients can help support bio-pharma companies with oncology assets in all stages of clinical development.

Key Learning Objectives:

Delegates will:

  • Learn about the major themes, challenges and opportunities for marketing an oncology therapy in combination, including clinical trial design, pricing, sequencing and product attributes, amongst others
  • Understand implications of combining therapies from more than one manufacturer, anticipated pricing challenges and considerations for indication expansion
  • Understand the payer environment in oncology across the US and EU and uncover what evidence payers are looking for to make decisions about combination therapies
  • Understand how KOLs see oncology market evolving and how combination therapies will be utilized
  • Understand what effect patient characteristics may have on eventual treatment choice
  • Learn how integrated insights across all stakeholder groups can benefit launch strategies

Register now: https://bit.ly/2L80Tme

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Will gene therapies finally be commercially viable to pharma?

Our latest Free Thinking white paper explores the science behind the idea of gene therapy and takes a look at some of the core challenges medical researchers have faced when...

Wargaming in HCV

The challenge:Our client had a product ready for launch in the HCV landscape. A number of new competitor products were expected to alter the market dynamics. Given the stage of...

Living with Lupus: Breaking the Silence

Published in eyeforpharma July 2017 by Mariel Metcalfe

Demystifying human-centred design: the application of iterative, human-centric approaches in global health market research

One of the biggest buzz topics in the global health community over the last couple of years has been human-centred design, also referred to as behaviour-centred design. In this blog...

In the news: What will the UK’s recent general election result and ongoing Brexit negotiations mean for DfID funding for global health?

The UK’s Department for International Development (DfID) was established in 1997 with a mandate to tackle world poverty. Since its inception, it has played a major role in the global...

EphMRA 2017 round up

We were delighted to present, exhibit and sponsor this year’s EphMRA Annual Conference in Amsterdam, Netherlands.

Taking a hybrid qualitative-quantitative approach to research

Directors Phil Rosenberg and Chris Gaj discuss ways to achieve qualitative insights with quantitative precision and the benefits of a hybrid approach.Watch the video: https://www.researchpartnership.com/news/2017/06/video-taking-a-hybrid-qualitative-quantitative-appr...

20th anniversary celebrations

We recently celebrated our 20th year anniversary with parties for our employees across the globe.Find out more and view the photos https://www.researchpartnership.com/news/2017/06/20th-anniversary-party-photos/

Pharma CI Asia Conference & Exhibition 2017

13-14 July 2017, Singapore

Director Richard Head is joint winner of the 2017 EphMRA President’s Award

We are delighted to announce that Research Partnership’s Richard Head is joint winner of the 2017 EphMRA President's Award for his contribution to pharmaceutical market research